Urinary endothelin-like immunoreactivity in patients with cirrhosis

Journal of Hepatology

Volumn 27, Issue 5, 1997, Pages 810-816

  Saló, Joan ^a   Fernández Esparrach, Glòria ^a   Ginès, Pere ^a   Ginès, Angels ^a   Guevara, Mónica ^a   Sort, Pau ^a   Jiménez, Wladimiro ^b   Arroyo, Vicente ^a   Rivera, Francisca ^b   Rodés, Juan ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Ascites; Cirrhosis; Endothelin; Hepatorenal syndrome

Indexed keywords

ENDOTHELIN;

ADULT; AGED; ARTICLE; ASCITES; DIURESIS; FEMALE; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; IMMUNOREACTIVITY; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER PERFUSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SODIUM RETENTION; URINARY EXCRETION; WATER RETENTION;

EID: 0343924653     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80317-0     Document Type: Article

References (49)

1. Ginès P, Arroyo V, Rodés J. Disorders of renal function in cirrhosis: pathophysiology and clinical aspects. Zakim D, Boyer J. 3rd ed. Hepatology. A Textbook of Liver Disease. I:1996;650-675 WB Saunders Company, Philadelphia.
2. Epstein M. 4th ed. The Kidney in Liver Disease. 1996;Hanley and Belfus Inc. Philadelphia.
3. Ginès P, Schrier RW. Hepatorenal syndrome and renal dysfunction associated with liver disease. Schrier RW, Gottschalk CW. 6th ed Diseases of the Kidney. II:1997;2099-2127 Little Brown and Company, Boston.
4. Goligorky MS, Nord EP. Endothelin and renal dysfunction in liver disease. Epstein M. 4th ed. The Kidney in Liver Disease. 1996;387-404 Hanley and Belfus, Inc. Philadelphia.
5. Uchihara M, Izumi N, Sato C, Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology. 16:1992;95-99.
6. Uemasu J, Matsumoto H, Kawasaki H. Increased plasma endothelin levels in patients with liver cirrhosis. Nephron. 60:1992;380-383.
7. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med. 327:1992;1774-1778.
8. Asbert M, Ginès A, Ginès P, Jiménez W, Clària J, Saló J, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology. 104:1993;1485-1491.
9. Moller S, Emmeluth C, Henriksen JH. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J Hepatol. 19:1993;285-290.
10. Matsumoto H, Uemasu J, Kitano M, Kawasaki H. Clinical significance of plasma endothelin-1 in patients with chronic liver disease. Dig Dis Sci. 39:1994;2665-2670.
11. Saló J, Francitorra A, Follo A, Navasa M, Ginès A, Jiménez W, et al. Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. J Hepatol. 22:1995;389-398.
12. Martinet JP, Legault L, Cernacek P, Roy L, Dufresne MP, Spahr L, et al. Changes in plasma endothelin-1 and Big endothelin-1 induced by transjugular intrahepatic portosystemic shunt in patients with cirrhosis and refractory ascites. J Hepatol. 25:1996;700-706.
13. Nord EP. Renal actions of endothelin. Kidney Int. 44:1993;451-463.
14. Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev. 73:1993;375-411.
15. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev. 72:1996;425-535.
16. Nadler SP, Zimpelmann JA, Hébert RL. Endothelin inhibits vasopressin-stimulated water permeability in rat terminal inner medullary collecting ducts. J Clin Invest. 90:1992;1458-1466.
17. Ando K, Hirata Y, Takei Y, Kawakami M, Marumo F. Endothelin-1-like immunoreactivity in human urine. Nephron. 57:1991;36-39.
18. Ohta K, Hirata Y, Shichiri M, Kanno K, Emori T, Tomita K, et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int. 39:1991;307-311.
19. Abassi ZA, Klein H, Glomob E, Keiser HR. Urinary endothelin: a possible biological marker of renal damage. Am J Hypertens. 6:1993;1046-1054.
20. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 23:1996;164-176.
21. Saló J, Ginès A, Quer JC, Fernández-Esparrach G, Guevara M, Ginès P, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol. 25:1996;916-923.
22. Asbert M, Jiménez W, Gaya J, Ginès P, Arroyo V, Rivera F, et al. Assessment of the renin- angiotensin system in cirrhotic patients: comparison between plasma renin activity and direct measurement of immunoreactive renin. J Hepatol. 15:1992;179-183.
23. Ginès P, Jiménez W, Arroyo V, Navasa M, López C, Titó LI, et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology. 8:1988;636-642.
24. Peuler JO, Johnson GA. Simultaneous single isotope radioenzymatic assays of plasma norepinephrine, epinephrine and dopamine. Life Sci. 21:1977;625-633.
25. Pérez Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int. 26:1984;72-80.
26. Terada Y, Tomita K, Nonoguchi H, Marumo F. Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Invest. 90:1992;107-112.
27. Wilkes BM, Susin M, Mento PF, Macica CM, Girardi EP, Boss E, et al. Localization of endothelin-like immunoreactivity in rat kidneys. Am J Physiol. 260:1991;F913-F920.
28. Ujie K, Terada Y, Nonoguchi H, Shinohara M, Tomita K, Marumo F. Messenger RNA expression and synthesis of endothelin-1 along rat nephron segments. J Clin Invest. 90:1992;1043-1048.
29. Uchida S, Takemoto F, Kurokawa K, Ogata E. Detection of endothelin (ET-1) mRNA by RT- PCR in microdissected nephron segments from rats. J Am Soc Nephrol. 2:1991;420A.
30. Karet FE, Davenport AP. Localization of endothelin peptides in human kidney. Kindey Int. 49:1996;382-387.
31. Karet FE, Davenport AP. Human kidney: endothelin isoforms detected by RP-HPLC with radioimmunoassay and receptor subtypes detected using ligands BQ123 and BQ3020. J Cardiovasc Pharm. 22:1993;S29-S33. (suppl 8).
32. Zeidel ML, Brady HR, Kone BC, Gullans SR, Brenner BM. Endothelin, a peptide inhibitor of NA(+)-K(+)-ATPase in intact renal tubular epitelial cells. Am J Physiol. 257:1989;C1101-C1107.
33. Tomita K, Nonoguchi H, Marumo F. Effects of endothelin on peptide-dependent cyclic adenosine monophosphate accumulation along the nephron segments of the rat. J Clin Invest. 85:1990;2014-2018.
34. Abassi ZA, Tate JE, Golomb E, Keiser HR. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension. 20:1992;89-95.
35. Benigni A, Perico N, Gaspari F, Zoja C, Bellizzi L, Gabanelli M, et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol. 260:1991;F331-F339.
36. Rocatello D, Mosso R, Ferro M, Polloni R, De Filippi PG, Quattrocchio G, et al. Urinary endothelin in glomerulonephritis patients with normal renal function. Clin Nephrol. 41:1994;323-330.
37. Lee YJ, Shin SJ, Tsai JH. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care. 17:1994;263-266.
38. Textor SC, Burnett JC, Romero JC, Canzanello VJ, Taler SJ, Wiesner R, et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 47:1995;1426-1433.
39. Gerbes AL, Moller S, Gülberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: a role of splanchnic and renal passage and liver function. Hepatology. 21:1995;735-739.
40. Ackerman Z, Karmeli F, Amir G, Rachmilewitz D. Renal vasoactive mediator generation in portal hypertensive and bile duct ligand rats. J Hepatol. 24:1996;478-486.
41. Leivas A, Jiménez W, Lamas S, Bosch-Marcé M, Oriola J, Clàra J, et al. Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. Gastroenterology. 108:1995;1842-1848.
42. Modesti Pa, Cecioni I, Naldoni A, Migliorini A, Serneri GN. Relationship of renin-angiotensin system and ET-1 system activation in long-lasting response to postural changes. Am J Physiol. 270:1996;H1200-H1206.
43. Kitano M, Uemasu J, Kawasaki H. Increased urinary endothelin excretion in patients with liver cirrhosis. J Gastroenterol Hepatol. 11:1996;347-352.
44. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 96:1982;413-417.
45. Arroyo V, Clàra J, Saló J, Jiménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis. 14:1994;44-58.
46. Moller S, Gülberg V, Henriksen JH, Gerbes AL. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol. 23:1995;135-144.
47. Gandhi CR, Sproat LA, Subbotin VM. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci. 58:1996;55-62.
48. Pinzani M, Milani S, Franco R, Grappone C, Caligiuri A, Gentilini A, et al. Endothelin-1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology. 110:1996;534-548.
49. Leivas A, Jiménez W, Bruix J, Boix L, Arroyo V, Rivera F, et al. La expresión génica de endotelina-1 (ET-1) y de sus receptores A y B se encuentra aumentada en pacientes cirróticos. Gastroenterol Hepatol. 19:1996;5.